Browsing Tag
Organon
8 posts
Sun Pharmaceutical (NSE: SUNPHARMA) bets $11.75bn on Organon (NYSE: OGN) to become a top global pharma player
Sun Pharma is borrowing scale to escape the generics trap. Organon could reshape its global pharma identity if execution holds.
Is Sun Pharmaceutical (NSE: SUNPHARMA) now a wait-for-results stock or an M&A rerating story?
Sun Pharmaceutical (NSE: SUNPHARMA) faces Q4 results, tariff risk, and the Organon bid. Read what could move the stock next.
Organon (NYSE: OGN) secures FDA approval for five-year use of NEXPLANON contraceptive implant, adding new REMS training requirement
Find out how Organon’s NEXPLANON just got FDA approval for five-year use—and what the new REMS program means for doctors and competitors.
Prolia and Xgeva just got rivals: FDA clears BILDYOS and BILPREVDA biosimilars for U.S. launch
The FDA has approved Henlius and Organon’s denosumab biosimilars. Find out what this means for U.S. bone health access, pricing, and investor sentiment.
Organon to acquire Dermavant for $1.2bn, expanding its presence in immuno-dermatology
Organon, a global healthcare company focused on women’s health, has announced a definitive agreement to acquire Dermavant Sciences…
Organon and Eli Lilly expand global reach of migraine treatment Emgality
Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into…
Granules India gains FDA approval for Losartan-Hydrochlorothiazide Tablets
Granules India Limited proudly announced today that the United States Food & Drug Administration (US FDA) has granted…
Organon, Samsung Bioepis launch HUMIRA biosimilar HADLIMA in US
Organon & Co. and Samsung Bioepis revealed that HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now accessible…